Blade(BLDE) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $66.8 million, driven by logistics growth, with organic growth of 35.3% to $49.2 million compared to $36.4 million in the prior year [22][24] - Full year 2025 revenue and adjusted EBITDA were $197.1 million and $14.1 million respectively, both exceeding the high end of guidance [22][24] - Adjusted EBITDA rose to $7 million in Q4 2025, up from $1.1 million in the year-ago period [25] Business Line Data and Key Metrics Changes - Logistics revenue increased to $49.2 million in Q4 2025, reflecting a 35.3% organic growth [22][24] - Clinical revenue was $17.6 million in Q4 2025, significantly up from $2.8 million in Q3 2025, due to the Keystone acquisition [22][23] - Gross profit increased 90% to $14.4 million in Q4 2025, with gross margin rising to 21.6% from 20.8% in the prior year [24][25] Market Data and Key Metrics Changes - Approximately 20% of revenue is generated from Organ Procurement Organizations (OPOs), with Tier One OPOs representing 2.4 times the revenue of Tier Three OPOs [10] - The company is well-positioned in the regulatory landscape, with a customer base over-indexed to larger, more sophisticated transplant centers [9][10] Company Strategy and Development Direction - The company is focusing on acquisitions of smaller businesses to accelerate growth and expand geographically [5][6] - A singular focus on medical services and the integration of Keystone is expected to enhance operational efficiency and customer offerings [7][8] - The company aims to maintain an average annualized adjusted EBITDA growth rate of at least 30% over the coming years [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the future, citing strong Q4 performance and continued growth into 2026 [5][27] - Regulatory updates are seen as positive, with expectations of increased organ transplants and improved patient safety [9][10] - The company anticipates a modest sequential revenue decline in Q1 2026 but expects improvement in the second quarter and back half of the year [29][30] Other Important Information - The company ended the year with approximately $61 million in cash and short-term investments and no debt [27] - A $30 million asset-based credit facility was closed to support acquisition strategies, with the ability to upsize to $50 million [15] Q&A Session Summary Question: Update on continuous distribution policy and stakeholders involved - Management noted that continuous distribution remains the goal for all organs, with lungs already transitioned and ongoing discussions for hearts and livers [32][34] Question: Breakdown of service value and customer usage of full service portfolio - Management indicated that transplant clinical business has slightly higher profit margins and that many clinical customers are beginning to utilize logistics services [36][38] Question: Acquisition pipeline and adjacent offerings - The company plans to announce acquisitions as they close and is focused on increasing scale and national footprint through product servicing [41][42] Question: Impact of weather on operations - Unusual severe weather in the Northeast affected operations, but management remains confident in overall performance and guidance [71][72] Question: Effect of higher oil prices on business - Increased fuel prices will result in higher costs for customers but will not impact the company's cost structure due to negotiated fuel surcharge thresholds [73][74]